General AML

David Sallman | ASH 2018 | Key results of the phase I THINK trial of NKG2D CAR-T therapy in R/R AML

L:

At the 2018 American Society of Hematology meeting, David A. Sallman from H. Lee Moffitt Cancer Center and Research Institute, Tampa, US discusses the results from the THINK trial, an open-label phase I study assessing the safety and clinical activity of multiple CYAD‑01 administrations without prior preconditioning in patients with relapsing/refractory (R/R) acute myeloid leukemia (AML).

Download this article:

You can now download this article in Adobe PDF® format.

Download as PDF
Was this article informative? Thank you for your feedback!
33% of people found this article informative